tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Toxocariasis D014120 3 associated lipids
Translocation, Genetic D014178 20 associated lipids
Tremor D014202 15 associated lipids
Trichomonas Infections D014245 3 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Trypanosomiasis D014352 5 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ulcer D014456 16 associated lipids
Uremia D014511 33 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urination Disorders D014555 9 associated lipids
Urticaria D014581 13 associated lipids
Uveitis D014605 14 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Vascular Diseases D014652 16 associated lipids
Vasculitis D014657 14 associated lipids
Venous Insufficiency D014689 2 associated lipids
Viremia D014766 4 associated lipids
Vision Disorders D014786 10 associated lipids
Vitiligo D014820 2 associated lipids
Vomiting D014839 21 associated lipids
West Nile Fever D014901 1 associated lipids
Wounds, Stab D014951 3 associated lipids
Dementia, Vascular D015140 7 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Discitis D015299 2 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Scleritis D015423 3 associated lipids
Reperfusion Injury D015427 65 associated lipids
Weight Gain D015430 101 associated lipids
Weight Loss D015431 56 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Histiocytosis D015614 2 associated lipids
HIV Infections D015658 20 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Granuloma Annulare D016460 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Fungemia D016469 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Foot Ulcer D016523 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Critical Illness D016638 13 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Liver Failure D017093 5 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Polymyositis D017285 1 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Hyperpigmentation D017495 11 associated lipids
Hypopigmentation D017496 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Porokeratosis D017499 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Friob MC et al. A combined HPLC-ELISA evaluation of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721265
Machida M et al. Effect of temperature and hematocrit on plasma concentration of FK 506. 1991 Transplant. Proc. pmid:1721266
Kawauchi M et al. Plasma level of FK 506 in newborn goats and infant baboons. 1991 Transplant. Proc. pmid:1721267
Iwasaki K et al. Pharmacokinetic study of FK 506 in the rat. 1991 Transplant. Proc. pmid:1721268
O'Neill EA et al. The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. 1991 Transplant. Proc. pmid:1721298
Nelson PA et al. Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. 1991 Transplant. Proc. pmid:1721299
Dumont FJ et al. Up-regulation of gene expression by FK 506. 1991 Transplant. Proc. pmid:1721300
Rao P et al. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. 1991 Transplant. Proc. pmid:1721301
Takai K et al. Immunosuppressive effects of FK 506 on rat lymphoid organs. 1991 Transplant. Proc. pmid:1721329
Ishibashi M et al. Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. 1991 Transplant. Proc. pmid:1721330
Kawauchi M et al. Flow cytometric analysis of lymphocyte populations in FK 506-treated newborn goats. 1991 Transplant. Proc. pmid:1721331
Borg AJ and Kumagai M FK 506 and xenogeneic human anti-porcine cellular reactivity. 1991 Transplant. Proc. pmid:1721332
McCauley J et al. Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. 1991 Transplant. Proc. pmid:1721362
Zeevi A et al. Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. 1991 Transplant. Proc. pmid:1703341
Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721363
van Hoek B et al. Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. 1991 Transplant. Proc. pmid:1703343
Jensen CW et al. Pediatric renal transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721364
McCauley J et al. The question of FK 506 nephrotoxicity after liver transplantation. 1991 Transplant. Proc. pmid:1703344
Jordan ML et al. FK 506 conversion of renal allografts failing cyclosporine immunosuppression. 1991 Transplant. Proc. pmid:1721365
Alessiani M et al. Infections in adult liver transplant patients under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703345
Scantlebury V et al. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. 1991 Transplant. Proc. pmid:1721395
Carroll PB et al. FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. 1991 Transplant. Proc. pmid:1721396
Freise CE et al. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. 1991 Transplant. Proc. pmid:1721397
Eidelman BH et al. Neurologic complications of FK 506. 1991 Transplant. Proc. pmid:1721398
Murase N et al. Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721424
Langrehr JM et al. Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. 1991 Transplant. Proc. pmid:1721425
Takeda Y et al. Effect of FK 506 on the survival of rat small bowel allografts. 1991 Transplant. Proc. pmid:1721426
Fukuzawa M et al. Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. 1991 Transplant. Proc. pmid:1721427
Brabletz T et al. The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. 1991 Nucleic Acids Res. pmid:1707162
Iwaki Y et al. Replacement of donor lymphoid tissue in small-bowel transplants. 1991 Lancet pmid:1707470
Markus PM et al. Effects of in vivo treatment with FK506 on natural killer cells in rats. 1991 Transplantation pmid:1707562
Roat MI et al. Treatment of Cogan's syndrome with FK 506: a case report. 1991 Transplant. Proc. pmid:1721457
Carroll PB et al. The use of FK 506 in new-onset type I diabetes in man. 1991 Transplant. Proc. pmid:1721458
McCauley J et al. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. 1991 Transplant. Proc. pmid:1721459
Carrieri G et al. Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. 1991 Transplant. Proc. pmid:1721460
Markus PM et al. FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. 1991 Surgery pmid:1713358
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Vathsala A et al. The immunosuppressive antagonism of low doses of FK506 and cyclosporine. 1991 Transplantation pmid:1713361
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Katayama Y et al. Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. 1991 Transplant. Proc. pmid:1703690
Thomson AW The immunosuppressive macrolides FK-506 and rapamycin. 1991 Immunol. Lett. pmid:1717376
Takaya S et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. 1991 Transplant. Proc. pmid:1703691
Steeves M et al. In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. 1991 J. Pharm. Pharmacol. pmid:1717676
Hildebrandt A et al. FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. 1991 Transplant. Proc. pmid:1703694
Unmasking immunosuppression. 1991 Lancet pmid:1717800
Ericzon BG et al. Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. 1991 Transplant. Proc. pmid:1703695
Altmeyer A et al. Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. 1991 Int. J. Immunopharmacol. pmid:1726093
Gordon RD et al. Liver transplantation at the University of Pittsburgh, 1984 to 1990. 1991 Clin Transpl pmid:1726458
Jamieson NV et al. Orthotopic liver transplantation at Addenbrooke's Hospital Cambridge 1968 to 1991. 1991 Clin Transpl pmid:1726459
Takahara S et al. Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK506. 1991 J Clin Lab Immunol pmid:1726566